Turbine secures €3m seed funding round

The round also saw participation from previous angel investors Esther Dyson and Vishal Gulati, and Atlantic Labs. New investor O2H Ventures, which launched an enterprise investment scheme fund backing early-stage biotech, also participated.

Delin partner Alan Barge, a former vice-president and head of oncology therapy at AstraZeneca, will join the board of directors of Turbine.

The funding will be used to redesign the oncology drug discovery process into a series of rational steps facilitated by Turbine's proprietary human cell model and simulation platform. The company expects to expand the simulation-based drug discovery workflow into every phase, from research to lifecycle management.

Company
Founded in 2015 and headquartered in Budapest, Tribune is a simulation-based drug discovery company that models how cancer works on the molecular level and tests millions of potential drugs on it with artificial intelligence.

Turbine was founded on the premise that a computational model of human cell biology would rationalise drug discovery the same way that computer-aided design revolutionised architecture.

The company employs around 50 staff, according to LinkedIn.

People
Turbine – Szabolcs Nagy (CEO).
Delin Ventures – Alan Barge (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• CEE
• Healthcare
• Venture
• Hungary